NEWS AND EVENTS

November 2009: Oncolix's CEO, Michael Redman will be delivering a corporate presentation at Texas Life Science Conference 2009. The conference will be held November 11 - 13, 2009 at the The Brown Foundation Institute of Molecular Medicine in Houston, Texas.

October 2009: Oncolix's CEO, Michael Redman will be delivering a corporate presentation at the 2009 Life Sciences and Healthcare Venture Summit, being held on October 27, 2009 in New York City.

September 2009: Oncolix's CEO, Michael Redman delivered a corporate presentation at BioPharm America™ 2009. The conference was held September 16 - 18, 2009 in San Francisco, California. Oncolix's CEO, Michael Redman delivered a corporate presentation Rodman & Renshaw's 11th Annual Healthcare Conference. The conference will be held September 9-11, 2009, at the Palace Hotel in New York City.

June 2009: Dr. Wen Chen's group presented two abstracts at the Endocrine Society’s Annual Meeting, Washington, DC, June 10 – 13, 2009. In vivo evidence of prolactin receptor antagonist, Prolanta™ (G129R), in inhibition of HER2/neu tumor. In vitro and in vivo data indicating prolactin receptor antagonist, Prolanta™ (G129R), suppressed mammary tumor stem cell populations measured by ALDH1 activity.

January 2009: Oncolix's CEO, Michael Redman presented at the Biotech Showcase 2009 San Francisco, CA, January 14, 2009.

June 2007: Dr. Wen Chen's group presented two abstracts at the Endocrine Society’s Annual Meeting, Toronto, Canada, June 2-5, 2007. A multifaceted, targeted, combination therapy using three novel prolactin receptor antagonists. Development of novel ligands that activate Jak2/Stat5 signaling exclusively through the heterodimer of a human prolactin receptor and a human growth hormone receptor.